[Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].
A liposomal drug DaunoXome was used as a single agent for stage III-IV breast cancer in 9 patients. Response was recorded in 6; partial regression of tumor--3, and stabilization of disease--in 3 cases. Nausea and vomiting were among the most frequent side-effects; stage I leukopenia was observed in 4; stage II--3, stage III--2 patients. No cardiotoxicity was reported.
Darskaia
E I
EI
Acad. I.P. Pavlov State Medical University, St. Petersburg.
Zubarovskaia
L S
LS
Afanas'ev
B V
BV
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004337:Drug Carriers; D005260:Female; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin